More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...

Polymorphs, or different crystalline forms of the same drug, can be selected for distinct properties and patented. A recent ...

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an ...

A leading top-3 CRO and a top-10 pharmaceutical company joined forces with Medable to transform their eCOA trial operations, overcoming lengthy setup times, fragmented designs, and disjointed ...

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

<p>Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.</p> ...

Leadership is about fostering the conditions for others to succeed. Empathy shapes how teams function, how trust is built, and how workplaces grow, writes Monica Singh Avram.